Wednesday, July 29, 2020

Roche#39;s Tocilizumab fails to meet primary end points for COVID-19 associated pneumonia

Roche#39;s Tocilizumab fails to meet primary end points for COVID-19 associated pneumonia However, Roche said there was a positive trend in time to hospital discharge in patients treated with Actemra. The median time to discharge or ‘ready to discharge’ for Actemra was 20 days and for placebo was 28 days.

from Moneycontrol Business News https://ift.tt/334PmjR
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

FIIs ease bearish bets post-Budget, but charts warn of range-bound Nifty: Anand James

Foreign investors are reducing their negative bets on the market after the Budget. However, the market's overall sentiment remains delic...